SAN FRANCISCO, Feb. 26, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the company has completed target enrollment in its REZOLVE-AA Phase 2b study of rezpegaldesleukin in ...

Nektar Therapeutics has concluded target enrolment in the Phase IIb REZOLVE-AA trial of its investigational biologic therapy, rezpegaldesleukin, for treating individuals with severe-to-very-severe ...

SAN FRANCISCO, July 29, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ...

A new study published in the journal of Acta Dermatovenerologica Alpina, Panonica, et Adriatica showed that the frequency of adolescent alopecia was very high, and it was more frequent in girls.

Rezpegaldesleukin is an investigational biologic therapy that targets the interleukin-2 receptor complex in the body in order to stimulate proliferation of inhibitory immune cells known as regulatory ...

If you’ve started to notice the early signs of hair loss, it’s easy to wonder what’s causing you to shed hair. Telogen effluvium and androgenetic alopecia are two common forms of hair loss. One causes ...